Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Response-Guided Neoadjuvant Radiochemotherapy in Chemotherapy-Resistant Esophageal Adenocarcinoma
2005-004123-19Phase 2Completed
- Sponsor
- Klinikum rechts der Isar
- Start
- Nov 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, cisplatin, oxaliplatin, fluorouracil and folinic acid in gastroesophageal adenocarcinoma, sponsored by Klinikum rechts der Isar. Primary endpoint: Metabolic response rate. Started Nov 2005; status: completed.
02
Drugs
paclitaxelcisplatinoxaliplatinfluorouracilfolinic acid
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2005-004123-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004123-19.